BioSpace News Archive

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company that the National Medical Products Administration of China has accepted the supplemental New Drug Application for TYVYT® in combination with Gemzar® and platinum as first-line therapy in squamous non-small cell lung cancer.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that Rosty Raykov, Chief Executive Officer of Fennec will present at the following upcoming investor conferences.

Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces the availability of its MolecuLight i:X® platform on theEpic App Orchard Marketplace and the integration of its platform with Epic’s leading EMR platform.

Vizient, Inc. , the nation’s largest health care performance improvement company, today announced an opportunity for minority-, women- and veteran-owned businesses to enroll in its Community Contracting Program, a new initiative designed to connect Vizient member hospitals with local, diverse suppliers and service providers. When launched to its member hospitals, Community Contracting will streamline identification and co

Cellular Biomedicine Group, Inc. announced today that it has signed a definitive merger agreement to be acquired by a newly-formed entity formed on behalf of a consortium consisting of Bizuo Liu and certain other members of CBMG management...

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce that it has recorded its first sale of OxC-beta™ Livestock in Brazil.

Omeros Corporation announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock at a public offering price of $14.50 per Share for proceeds of approximately $100,050,000, prior to the deduction of underwriting discounts and commissions and estimated offering expenses payable by Omeros, and $210,000,000 aggregate principal amount of 5.25% convertible senior notes due 2026.

TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%

WALTHAM, MA / ACCESSWIRE / August 12, 2020 / EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that it has received positive feedback following its pre-IND meeting with the U.S. Food and Drug Administration and has been provided a path forward for the development of MoxiGel, a combination product for the treatment of bacterial conjunctivitis.